Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation
Leukotrienes (LTs) are proinflammatory lipid mediators synthesized by the conversion of arachidonic acid (AA) to LTA 4 by the enzyme 5-lipoxygenase (5-LO) in the presence of 5-LO-activating protein (FLAP). 3-[3- tert -Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1 H -i...
Gespeichert in:
Veröffentlicht in: | The Journal of pharmacology and experimental therapeutics 2009-12, Vol.331 (3), p.1042-1050 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Leukotrienes (LTs) are proinflammatory lipid mediators synthesized by the conversion of arachidonic acid (AA) to LTA 4 by the enzyme 5-lipoxygenase (5-LO) in the presence of 5-LO-activating protein (FLAP). 3-[3- tert -Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethyl-propionic acid (AM103) is a novel selective FLAP inhibitor in development for the treatment of respiratory
conditions such as asthma. In a rat ex vivo whole-blood calcium ionophore-induced LTB 4 assay, AM103 (administered orally at 1 mg/kg) displayed >50% inhibition for up to 6 h with a calculated EC 50 of â¼60 nM. When rat lung was challenged in vivo with calcium ionophore, AM103 inhibited LTB 4 and cysteinyl leukotriene (CysLT) production with ED 50 values of 0.8 and 1 mg/kg, respectively. In this model, the EC 50 derived from plasma AM103 was â¼330 nM for inhibition of both LTB 4 and CysLT. In an acute inflammation setting, AM103 displayed dose-dependent inhibition of LTB 4 , CysLT, and plasma protein extravasation induced by peritoneal zymosan injection. In a model of chronic lung inflammation
using ovalbumin-primed and challenged BALB/c mice, AM103 reduced the concentrations of eosinophil peroxidase, CysLTs, and
interleukin-5 in the bronchoalveolar lavage fluid. Finally, AM103 increased survival time in mice exposed to a lethal intravenous
injection of platelet-activating factor. In summary, AM103 is a novel, potent and selective FLAP inhibitor that has excellent
pharmacodynamic properties in vivo and is effective in animal models of acute and chronic inflammation and in a model of lethal
shock. |
---|---|
ISSN: | 0022-3565 1521-0103 |
DOI: | 10.1124/jpet.109.158089 |